Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Abstract 5353: PIK3CA and PTEN mutations as drivers of osimertinib resistance in patients with NSCLC

Ursula Grazini, Daniel J. O'Neill, Matthew Martin, Chintia Xu, Nicolas Floch, Paul D. Smith, Emanuela Cuomo

Cancer Res (2022) 82 (12_Supplement): 5353.

https://doi.org/10.1158/1538-7445.AM2022-5353

Published: 15 June 2022

View article titled, Abstract 5353: PIK3CA and PTEN mutations as drivers of osimertinib resistance in patients with NSCLC

Journal Articles

Abstract 4217: MEKi in combination with anti-OX40 generates metabolically fit effector CD8⁺ T cells, enhances stem cell-like memory CD8⁺ T cells, and leads to strong anti-tumor activity

Pankaj Gaur, Vivek Verma, Mays Alreem Elayyan, Zainab Ramlaoui, Simon T. Barry, Viia E. Valge-Archer, Paul D. Smith, Seema Gupta, Samir N. Khleif

Cancer Res (2022) 82 (12_Supplement): 4217.

https://doi.org/10.1158/1538-7445.AM2022-4217

Published: 15 June 2022

View article titled, Abstract 4217: MEKi in combination with anti-OX40 generates metabolically fit effector CD8+ T cells, enhances stem cell-like memory CD8+ T cells, and leads to strong anti-tumor activity

Journal Articles

Abstract 923: Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in Kras mutant lung cancer

Hyejin Choi, Jiehui Deng, Shuai Li, Tarik Silk, Lauren Dong, Elliott J. Brea, Sean Houghton, David Redmond, Hong Zhong, Jonathan Boiarsky, Esra A. Akbay, Paul D. Smith, Taha Merghoub, Kwok-Kin Wong, Jedd D. Wolchok

Cancer Res (2020) 80 (16_Supplement): 923.

https://doi.org/10.1158/1538-7445.AM2020-923

Published: 15 August 2020

View article titled, Abstract 923: Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in Kras mutant lung cancer

Journal Articles

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Cancer Res (2020) 80 (10): 2017–2030.

https://doi.org/10.1158/0008-5472.CAN-19-3819

Published: 15 May 2020

View article titled, Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Includes: Supplementary data

Journal Articles

Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation

Nicolas Floch, M. Raymond V. Finlay, Ambra Bianco, Sue Bickerton, Nicola Colclough, Darren A. Cross, Emanuela M. Cuomo, Carine M. Guerot, David Hargreaves, Matthew J. Martin, Darren McKerrecher, Daniel J. O’Neill, Jonathan P. Orme, Amar Rahi, Paul D. Smith, Richard A. Ward

Cancer Res (2019) 79 (13_Supplement): 4451.

https://doi.org/10.1158/1538-7445.AM2019-4451

Published: 01 July 2019

View article titled, Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation

Journal Articles

Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)

Richard A. Ward, Ambra Bianco, Nicola Colclough, Darren Cross, Emanuela M. Cuomo, M. Raymond V. Finlay, Martina Fitzek, Nicolas Floc’h, Sladjana Gagrica, Beverley Hammond, Matthew J. Martin, Darren McKerrecher, Daniel J. O’Neill, Jonathan P. Orme, Paul D. Smith, Anna D. Staniszewska, Jelena Urosevic, Nicky Whalley, James W. Yates

Cancer Res (2019) 79 (13_Supplement): 4813.

https://doi.org/10.1158/1538-7445.AM2019-4813

Published: 01 July 2019

View article titled, Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)

Journal Articles

Abstract 1330: Osimertinib, an irreversible next generation EGFR tyrosine kinase inhibitor, exerts anti-tumor activity in various preclinical NSCLC models harboring G719X mutant-EGFR

Nicolas Floch, Sue Bickerton, Matthew J. Martin, Darren A. Cross, Paul D. Smith

Cancer Res (2019) 79 (13_Supplement): 1330.

https://doi.org/10.1158/1538-7445.AM2019-1330

Published: 01 July 2019

View article titled, Abstract 1330: Osimertinib, an irreversible next generation EGFR tyrosine kinase inhibitor, exerts anti-tumor activity in various preclinical NSCLC models harboring G719X mutant-EGFR

Journal Articles

Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547

Sjors M. Kas, Julian R. de Ruiter, Koen Schipper, Eva Schut, Lorenzo Bombardelli, Ellen Wientjens, Anne Paulien Drenth, Renske de Korte-Grimmerink, Sunny Mahakena, Christopher Phillips, Paul D. Smith, Sjoerd Klarenbeek, Koen van de Wetering, Anton Berns, Lodewyk F.A. Wessels, Jos Jonkers

Cancer Res (2018) 78 (19): 5668–5679.

https://doi.org/10.1158/0008-5472.CAN-18-0757

Published: 01 October 2018

View article titled, Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547

Includes: Supplementary data

Journal Articles

Abstract 916: A screen to target EGFR (C797S) in osimertinib-resistant lung cancer identifies brigatinib-based combinations that synergistically inhibit cell growth

Matthew J. Martin, Nicolas Floc'h, Chrysiis Michaloglou, M Raymond Finlay, Richard A. Ward, Paul D. Smith, Darren A. Cross

Cancer Res (2018) 78 (13_Supplement): 916.

https://doi.org/10.1158/1538-7445.AM2018-916

Published: 01 July 2018

View article titled, Abstract 916: A screen to target EGFR (C797S) in osimertinib-resistant lung cancer identifies brigatinib-based combinations that synergistically inhibit cell growth

Journal Articles

Abstract 4717: MAP kinase inhibition induces metabolic reprogramming in T-cells leading to induction of stem cell memory CD8 cells that enhance potency of adoptive cell therapy and anti-OX40 antibody

Vivek Verma, Shamim Ahmad, Peng Zeng, Mikayel Mkrtichyan, Simon T. Barry, Paul D. Smith, Paulo C. Rodriguez, John E. Janik, Seema Gupta, Samir N. Khleif

Cancer Res (2018) 78 (13_Supplement): 4717.

https://doi.org/10.1158/1538-7445.AM2018-4717

Published: 01 July 2018

View article titled, Abstract 4717: MAP kinase inhibition induces metabolic reprogramming in T-cells leading to induction of stem cell memory CD8 cells that enhance potency of adoptive cell therapy and anti-OX40 antibody

Journal Articles

New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome

Leah J. Wilson, Adam Linley, Dean E. Hammond, Fiona E. Hood, Judy M. Coulson, David J. MacEwan, Sarah J. Ross, Joseph R. Slupsky, Paul D. Smith, Patrick A. Eyers, Ian A. Prior

Cancer Res (2018) 78 (1): 15–29.

https://doi.org/10.1158/0008-5472.CAN-17-2291

Published: 02 January 2018

View article titled, New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome

Includes: Supplementary data

Journal Articles

MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy

Mounia Beloueche-Babari, Slawomir Wantuch, Teresa Casals Galobart, Markella Koniordou, Harold G. Parkes, Vaitha Arunan, Yuen-Li Chung, Thomas R. Eykyn, Paul D. Smith, Martin O. Leach

Cancer Res (2017) 77 (21): 5913–5924.

https://doi.org/10.1158/0008-5472.CAN-16-2686

Published: 31 October 2017

View article titled, MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy

Includes: Supplementary data

Journal Articles

Abstract 444: Monocarboxylate transporter 1 inhibition with AZD3965 increases cancer cell dependence on bioenergetic metabolism predicating combination therapy with mitochondrial inhibitors

Mounia Beloueche-Babari, Teresa Casals Galobart, Slawomir Wantuch, Paul D. Smith, Martin O. Leach

Cancer Res (2017) 77 (13_Supplement): 444.

https://doi.org/10.1158/1538-7445.AM2017-444

Published: 01 July 2017

View article titled, Abstract 444: Monocarboxylate transporter 1 inhibition with AZD3965 increases cancer cell dependence on bioenergetic metabolism predicating combination therapy with mitochondrial inhibitors

Journal Articles

Abstract 4184: Pre-clinical study using KRAS mutant mouse models for lung cancer immunotherapy together with MEK inhibition

Jiehui Deng, Shuai Li, Grit Herter-Sprie, Paul D. Smith, Gordon J. Freeman, Jeffrey A. Engelman, Peter Hammerman, Kwok-Kin Wong

Cancer Res (2016) 76 (14_Supplement): 4184.

https://doi.org/10.1158/1538-7445.AM2016-4184

Published: 15 July 2016

View article titled, Abstract 4184: Pre-clinical study using KRAS mutant mouse models for lung cancer immunotherapy together with MEK inhibition

Journal Articles

Abstract 270: Preclinical assessment of combination therapy with selumetinib and CTLA-4 for cancer

Stefanie R. Mullins, Edmund Poon, Amanda Watkins, Paul D. Smith, Andrew Leishman, Ross Stewart, Robert Wilkinson

Cancer Res (2015) 75 (15_Supplement): 270.

https://doi.org/10.1158/1538-7445.AM2015-270

Published: 01 August 2015

View article titled, Abstract 270: Preclinical assessment of combination therapy with selumetinib and CTLA-4 for cancer

Journal Articles

Abstract 477: Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma

Adam W. Studebaker, Kathryn Bondra, Star Seum, Justin Leasure, Christopher Chronowski, Changxian Shen, Doris Phelps, Paul D. Smith, Raushan T. Kurmasheva, Xiaokui Mo, Peter J. Houghton

Cancer Res (2015) 75 (15_Supplement): 477.

https://doi.org/10.1158/1538-7445.AM2015-477

Published: 01 August 2015

View article titled, Abstract 477: Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma

Journal Articles

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Cancer Res (2015) 75 (12): 2489–2500.

https://doi.org/10.1158/0008-5472.CAN-14-3167

Published: 14 June 2015

View article titled, Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Includes: Supplementary data

Journal Articles

Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma

Cancer Res (2014) 74 (23): 7037–7047.

https://doi.org/10.1158/0008-5472.CAN-14-1392

Published: 30 November 2014

View article titled, Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma

Includes: Supplementary data

Journal Articles

Abstract 1042: Maintenance or switch maintenance therapy with selumetinib or cediranib after chemoradiation prolongs survival in an orthotopic human lung cancer model.

Osamu Takahashi, Ritsuko U. Komaki, Juliane M. Jürgensmeier, Paul D. Smith, Ignacio I. Wistuba, Ramesh C. Tailor, Joerg J. Jacoby, Maria V. Korshunova, Yong Bae Kim, Baruch Erez, Roy S. Herbst, Michael S. O'Reilly

Cancer Res (2013) 73 (8_Supplement): 1042.

https://doi.org/10.1158/1538-7445.AM2013-1042

Published: 15 April 2013

View article titled, Abstract 1042: Maintenance or switch maintenance therapy with selumetinib or cediranib after chemoradiation prolongs survival in an orthotopic human lung cancer model.

Journal Articles

Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .

Fabrice Andre, Malcolm Ranson, Emma Dean, Andrea Varga, Ruud van der Noll, Paul K. Stockman, Dana Ghiorghiu, Elaine Kilgour, Paul D. Smith, Merran Macpherson, Peter Lawrence, Andrew Hastie, Jan HM Schellens

Cancer Res (2013) 73 (8_Supplement): LB-145.

https://doi.org/10.1158/1538-7445.AM2013-LB-145

Published: 15 April 2013

View article titled, Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .

NARROW

Abstract 5353: PIK3CA and PTEN mutations as drivers of osimertinib resistance in patients with NSCLC

Abstract 4217: MEKi in combination with anti-OX40 generates metabolically fit effector CD8⁺ T cells, enhances stem cell-like memory CD8⁺ T cells, and leads to strong anti-tumor activity

Abstract 923: Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in Kras mutant lung cancer

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation

Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)

Abstract 1330: Osimertinib, an irreversible next generation EGFR tyrosine kinase inhibitor, exerts anti-tumor activity in various preclinical NSCLC models harboring G719X mutant-EGFR

Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547

Abstract 916: A screen to target EGFR (C797S) in osimertinib-resistant lung cancer identifies brigatinib-based combinations that synergistically inhibit cell growth

Abstract 4717: MAP kinase inhibition induces metabolic reprogramming in T-cells leading to induction of stem cell memory CD8 cells that enhance potency of adoptive cell therapy and anti-OX40 antibody

New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome

MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy

Abstract 444: Monocarboxylate transporter 1 inhibition with AZD3965 increases cancer cell dependence on bioenergetic metabolism predicating combination therapy with mitochondrial inhibitors

Abstract 4184: Pre-clinical study using KRAS mutant mouse models for lung cancer immunotherapy together with MEK inhibition

Abstract 270: Preclinical assessment of combination therapy with selumetinib and CTLA-4 for cancer

Abstract 477: Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma

Abstract 1042: Maintenance or switch maintenance therapy with selumetinib or cediranib after chemoradiation prolongs survival in an orthotopic human lung cancer model.

Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only